36:T4c6,ALIVE is a pioneer mid-to-late stage HealthTech fund leveraging an exclusive ecosystem of strategic partners comprising leading hospital chains, HMOs and financial institutions to support and accelerate portfolio companies clinical and commercial expansion. Our unique strategic ecosystem and teams active engagement help portfolio companies realize their full potential and achieve large-scale success. By providing unparalleled access to invaluable resources in the form of:

Clinical infrastructures
KOLs
Big data
Domain experts
Financial backing

we help our companies gain an in-depth understanding of clinical workflows and procedures, to ensure product-market fit under challenging health economics, deliver better care for patients and create value to all stake holders. We invest in promising mid-to-late stage companies developing innovative platform technologies that will become the gold standard in a broad range of disciplines. We look for highly fundable companies with strong management, broad IP protection and a proven track record of execution, that are poised to benefit from the strategic synergies offered by the ALIVE ecosystem.37:T431,From biopharmaceuticals to medical devices, diagnostics, and healthcare services, OrbiMed is scouting the globe for innovations that will help ensure humanity lives healthier, longer and more productive lives. We have been investing globally for over 20 years across the healthcare industry: from early-stage private companies to large multinational corporations. Our team of over 80 distinguished scientific, medical, investment and other professionals manages over $13 billion across public and private company investments worldwide.

Life Sciences Focus

The global healthcare industry sits at the intersection of several powerful long-term growth trends led by global demographics and the ineluctable advance of scientific innovation in treating disease. These trends have caused a steady increase in the level of healthcare spending in the industrialized world, led by the U.S. which now spends over 17% of its GDP on healthcare. The healthcare industry's powerful growth profile coupled with its magnitude and complexity create myriad investment opportunities.

Magenta Medical Series C

Magenta Medical Series C